Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BBIO - BridgeBio Pharma, Inc.

IEX Last Trade
28.56
2.580   9.034%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:17:44 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%
$25.98
2.58
9.93%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
31%
Profitability 37%
Dept financing 25%
Liquidity 73%
Performance 16%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
7.70%
1 Month
4.93%
3 Months
16.40%
6 Months
22.03%
1 Year
-30.52%
2 Year
262.06%
Key data
Stock price
$28.56
P/E Ratio 
-11.54
DAY RANGE
$25.98 - $27.78
EPS 
-$2.58
52 WEEK RANGE
$22.94 - $44.32
52 WEEK CHANGE
-$35.00
MARKET CAP 
5.237 B
YIELD 
N/A
SHARES OUTSTANDING 
188.033 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
1.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,174,069
AVERAGE 30 VOLUME 
$2,588,663
Company detail
CEO: Neil Kumar
Region: US
Website: bridgebio.com
Employees: 400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a stabilizer of transthyretin, or TTR.

Recent news